Pfizer kills hemophilia gene therapy deal, imperiling Sangamo STATSangamo shares plunge after Pfizer ends hemophilia A gene therapy deal ReutersSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec Business WireSangamo Plunges After Pfizer Ends Pact for Hemophilia Treatment BloombergSangamo Biosciences Faces Pfizer Collaboration Termination TipRanks
Click here to Read more
